title: Advantages of using thalidomide for the management of refractory myeloma patients.
abstract: A group of 11 heavily pretreated patients receiving low-dose thalidomide was compared with a similar group of 10 patients with refractory myeloma treated with a convention-al oral chemotherapy. This study shows that thalidomide is not only effective in controlling the neoplastic clone but more-over, thanks to its low toxicity, allows out-patient management of these subjects.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Corso
authors.forename: Angela
authors.initials: A
authors.lastname: Lorenzi
authors.forename: Ester
authors.initials: E
authors.lastname: Orlandi
authors.forename: Cesare
authors.initials: C
authors.lastname: Astori
authors.forename: Silvia
authors.initials: S
authors.lastname: Mangiacavalli
authors.forename: Mario
authors.initials: M
authors.lastname: Lazzarino
mesh_terms: D000368:Aged; D000553:Ambulatory Care; D019468:Disease Management; D004341:Drug Evaluation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000633:toxicity; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D012189:Retrospective Studies; D016879:Salvage Therapy; D013792:Thalidomide / Q000008:administration & dosage* / Q000633:toxicity
chemical_list: D007166:Immunosuppressive Agents; D013792:Thalidomide